Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells $66,442.56 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 804 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $4,489,335.36. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Performance

Disc Medicine stock opened at $78.84 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The firm has a market cap of $301.96 million, a price-to-earnings ratio of -11.98 and a beta of 1.00. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The firm’s 50 day moving average price is $74.60 and its two-hundred day moving average price is $69.91.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, research analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Institutional Trading of Disc Medicine

Large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its stake in shares of Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after acquiring an additional 144 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after acquiring an additional 215 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in Disc Medicine by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after purchasing an additional 216 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Disc Medicine by 3.3% during the fourth quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after purchasing an additional 296 shares during the last quarter. Finally, State of Wyoming purchased a new position in Disc Medicine in the second quarter valued at about $25,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IRON shares. Morgan Stanley upped their target price on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Wedbush restated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. HC Wainwright upped their price objective on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $106.00.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.